STOCK TITAN

BULLFROG AI HLDGS INC - BFRG STOCK NEWS

Welcome to our dedicated page for BULLFROG AI HLDGS news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on BULLFROG AI HLDGS stock.

BullFrog AI Holdings Inc. (NASDAQ: BFRG) is a biotechnology innovator using artificial intelligence to accelerate drug discovery and clinical development. This news hub provides investors and industry professionals with timely updates on the company's AI-driven research initiatives, strategic partnerships, and therapeutic advancements.

Access consolidated information on BFRG's latest press releases including clinical trial progress, regulatory milestones, and technology developments related to its proprietary bfLEAP platform. Our curated collection serves as an essential resource for tracking advancements in precision medicine and AI-powered pharmaceutical research.

Key updates cover therapeutic focus areas such as liver disease treatments, obesity research, and neuropsychiatric disorder solutions. Stay informed about collaborative projects with leading research institutions and data-driven breakthroughs in biomarker discovery.

Bookmark this page for direct access to BullFrog AI's official announcements and third-party analysis. Regularly updated content ensures you maintain current awareness of the company's position at the intersection of biotechnology and artificial intelligence innovation.

Rhea-AI Summary

Bullfrog AI Holdings (NASDAQ: BFRG) has announced an exclusive live investor webinar and Q&A session scheduled for April 23, 2025, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Vin Singh discussing the company's innovative approach to drug development using AI and machine learning.

The presentation will showcase their proprietary bfLEAP™ platform, developed at Johns Hopkins Applied Physics Lab and a finalist for the R&D 100 Awards. This platform helps biopharma companies analyze high-dimensional, multi-modal data to optimize clinical strategies. The company's growth strategy focuses on two main areas: generating recurring revenue through their Data Networks platform and developing licensed drug assets in partnership with leading research institutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary

BullFrog AI Holdings (NASDAQ: BFRG) has entered into a collaboration agreement with Eleison Pharmaceuticals to optimize their Phase 3 clinical trial. The partnership will utilize BullFrog's Data Networks™ AI solution, powered by the bfLEAP® platform, to analyze clinical data from Eleison's ongoing Phase 3 trial of glufosfamide for pancreatic cancer.

The AI platform will focus on:

  • Evaluating trial trajectory regarding safety signals
  • Extracting predictive biomarkers for efficacy and safety
  • Supporting future trial design
  • Providing data-driven insights for Eleison's planned clinical trials

Glufosfamide, a third-generation alkylating agent, is being evaluated for second-line treatment of pancreatic cancer, which affects over 67,000 Americans and 510,000 people worldwide annually, with five-year survival rates below 5%. Eleison expects to complete the Phase 3 trial in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.34%
Tags
-
Rhea-AI Summary

BullFrog AI (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company using artificial intelligence (AI) and machine learning, announced its participation in the TechBio track at Biotech Showcase and RESI JPM during the JP Morgan Healthcare Conference in San Francisco from January 13–16, 2025.

At these events, BullFrog AI will present its proprietary BullFrog Data Networks®, powered by the bfLEAP™ platform. This tool analyzes high-dimension, multi-modal data in specific disease indications, offering a visual representation of previously unknown relationships and pathways. The platform integrates various data sources, including public datasets like the Human Cell Atlas (HCA) and The Cancer Genome Atlas (TCGA), as well as proprietary data.

The BullFrog Data Networks® address the challenge of turning complex datasets into actionable insights, aiding in target identification, understanding mechanisms of action, optimizing clinical trials, and drug repurposing. The platform aims to reduce timelines and improve outcomes in drug development by providing intuitive visual insights and streamlining development processes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences AI
Rhea-AI Summary

BullFrog AI Holdings (NASDAQ: BFRG) released a stockholder letter highlighting key achievements in 2024. The company enhanced its bfLEAP™ platform by integrating new AI technologies licensed from Johns Hopkins University. Through collaboration with the Lieber Institute for Brain Development, they identified novel drug targets for neuropsychiatric disorders. Their research on BF-114 showed promise in treating obesity and liver diseases, while BF-223 secured additional patent protection for oncology applications.

The company strengthened its leadership by adding Dr. Thomas W. Chittenden as CSO and Dr. John Baldoni to the Scientific Advisory Board. BullFrog AI raised $8.83 million through two equity offerings in 2024, maintaining a strong cash position for future growth initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
AI
-
Rhea-AI Summary

BullFrog AI Holdings (NASDAQ: BFRG) has appointed Josh Blacher as its new Chief Financial Officer, following the passing of former CFO Dane Saglio. Blacher brings over two decades of experience in strategic finance and corporate development for life science and biotech companies. His background includes roles as CFO at Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics, and senior positions at Teva Pharmaceuticals.

Blacher, who holds a BA in Economics from Yeshiva University and an MBA from Columbia Business School, will focus on strengthening the company's balance sheet, financial operations, and supporting strategic initiatives. His expertise includes SEC reporting, investor relations, and experience with both private and public companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.4%
Tags
management AI
-
Rhea-AI Summary

BullFrog AI (NASDAQ: BFRG; BFRGW) announced that its VP of Artificial Intelligence, Dr. Enrique García-Rivera, will present at Google's inaugural Cancer AI Symposium on October 30, 2024, in Boston. The presentation will showcase BullFrog AI's use of AI in drug discovery and development, focusing on their proprietary bfLEAP™ platform. This platform integrates multimodal biological data to accelerate drug development, particularly in cancer research.

Dr. García-Rivera will highlight the company's collaboration with the Lieber Institute for Brain Development, demonstrating bfLEAP™'s versatility across various therapeutic areas. He will also introduce BullFrog AI's novel 'AlgoLLM' system for gene prioritization, which uses large language models to streamline the discovery of actionable insights in neuropsychiatric disorders and other diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
conferences AI
Rhea-AI Summary

WallachBeth Capital announced the closing of BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) registered direct offering and concurrent private placement. The offering included:

  • 1,565,000 shares of common stock (or equivalents)
  • Common warrants to purchase up to 1,565,000 shares
  • Combined purchase price of $2.00
  • Gross proceeds of approximately $3.13 million

The warrants have an exercise price of $2.00 per share, are exercisable after six months, and expire five years from the initial exercise date. WallachBeth Capital, acted as sole placement agent for the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
private placement offering AI
-
Rhea-AI Summary

BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) has closed a previously announced definitive agreement for a registered direct offering and concurrent private placement. The company sold an aggregate of 1,565,000 shares of common stock (or equivalents) and warrants to purchase up to 1,565,000 shares at a combined price of $2.00. The gross proceeds from the offering are expected to be approximately $3.13 million.

The warrants have an exercise price of $2.00 per share, are initially exercisable six months from issuance, and will expire five years from the initial exercise date. WallachBeth Capital, acted as the sole placement agent for the offering. The shares and pre-funded warrants were issued under an effective shelf registration statement, while the common warrants were offered through a private placement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
private placement offering AI
-
Rhea-AI Summary

WallachBeth Capital announced that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has entered into a definitive agreement for a registered direct offering and concurrent private placement. The offering includes:

  • 1,565,000 shares of common stock (or equivalents)
  • Common warrants to purchase up to 1,565,000 shares
  • Combined purchase price of $2.00
  • Warrant exercise price of $2.00 per share

The gross proceeds are expected to be approximately $3.13 million. The closing is anticipated around October 21, 2024. WallachBeth Capital, is acting as the sole placement agent for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.77%
Tags
private placement offering AI
Rhea-AI Summary

BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) has announced a registered direct offering and concurrent private placement for aggregate gross proceeds of $3.13 million. The offering includes:

- 1,565,000 shares of common stock (or equivalents)
- Common warrants to purchase up to 1,565,000 shares
- Combined purchase price of $2.00
- Warrant exercise price of $2.00 per share

The warrants will be initially exercisable six months from issuance and expire five years from the initial exercise date. The offering is expected to close around October 21, 2024. WallachBeth Capital, is acting as the sole placement agent for the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.77%
Tags
private placement offering AI
BULLFROG AI HLDGS INC

Nasdaq:BFRG

BFRG Rankings

BFRG Stock Data

15.63M
6.97M
29.2%
11.72%
6.24%
Health Information Services
Pharmaceutical Preparations
Link
United States
GAITHERSBURG